Gemcitabine in patients with intraductal papillary mucinous neoplasm with an associated invasive carcinoma of the pancreas

Taiga Otsuka, Chigusa Morizane, Satoshi Nara, Hideki Ueno, Shunsuke Kondo, Kazuaki Shimada, Tomoo Kosuge, Masafumi Ikeda, Nobuyoshi Hiraoka, Takuji Okusaka

Research output: Contribution to journalArticlepeer-review

6 Scopus citations


Objectives: The standard chemotherapy for invasive ductal carcinoma of the pancreas (IDC) is gemcitabine; however, the efficacy of gemcitabine in invasive intraductal papillary mucinous neoplasm with an associated invasive carcinoma of the pancreas (IPMN-IC) is still unknown. Methods: Because it is difficult to distinguish between IPMN-IC and IDC based only on radiological findings in advanced unresectable cases, recurrent cases after surgical resection were analyzed to identify the efficacy of gemcitabine monotherapy for IPMN-IC. Results: Between 1992 and 2010, 128 patients with IPMN-IC and 548 patients with IDC underwent pancreatic resection at the National Cancer Center Hospital. Twelve patients with IPMN-IC and 73 patients with IDC had recurred after surgery and subsequently underwent gemcitabine at the standard dosage. The disease-control rates were comparable between the IPMN-IC and IDC patients (58.3% vs 59.4%). The median progression-free survival was 2.8 and 4.1 months in the IPMN-IC and IDC patients, respectively (P = 0.46). Also, no statistically significant difference in the median survival times was observed between the 2 groups (9.3 vs 8.8 months, respectively; P = 0.09). Conclusions: Among patients who had IPMN-IC and IDC with recurrent disease after resection, there was no significant difference in treatment outcomes after gemcitabine.

Original languageEnglish
Pages (from-to)889-892
Number of pages4
Issue number5
StatePublished - Jul 2013
Externally publishedYes


  • Chemotherapy
  • Intraductal papillary mucinous carcinoma
  • Invasive ductal carcinoma of the pancreas
  • IPMC
  • IPMN
  • Pancreatic cancer

Cite this